科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02171 科济药业-B

未开盘 11-18 16:08:08

6.290

+0.190

+3.11%

最高6.650	最低6.000	成交量1,208万
今开6.000	昨收6.100	日振幅10.66%
总市值35.95亿	流通市值35.95亿	总股本5.72亿
成交额7,682万	换手率2.11%	流通股本5.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"科济药业-B","latestPrice":6.29,"timestamp":1731917288015,"preClose":6.1,"halted":0,"volume":12083000,"delay":0,"floatShares":571539915,"shares":571539915,"eps":-1.4477633,"marketStatus":"未开盘","marketStatusCode":0,"change":0.19,"latestTime":"11-18 16:08:08","open":6,"high":6.65,"low":6,"amount":76817400,"amplitude":0.106557,"askPrice":6.29,"askSize":1500,"bidPrice":6.28,"bidSize":10500,"shortable":3,"etf":0,"ttmEps":-1.3434412988207822,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731979800000},"adr":0,"listingDate":1623945600000,"adjPreClose":6.1,"openAndCloseTimeList":[[1731893400000,1731902400000],[1731906000000,1731916800000]],"volumeRatio":0.5269520192474682,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171/wiki","defaultTab":"wiki","newsList":[{"id":"2484718627","title":"科济药业-B授出266.7万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2484718627","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484718627?lang=zh_cn&edition=full","pubTime":"2024-11-18 21:27","pubTimestamp":1731936425,"startTime":"0","endTime":"0","summary":"格隆汇11月18日丨科济药业-B(02171.HK)公告，于2024年11月18日，公司根据首次公开发售后购股权计划的条款向三十一名购股权承授人授出266.7万份购股权，授出购股权的行使价每股股份7.26港元。授出购股权旨在激励购股权承授人为公司作出贡献，并使其利益与公司及股东整体的最佳利益保持一致，及╱或奖励彼等过往对公司成功所作的贡献。【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱：news_center@staff.hexun.com","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118213207abcc92ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118213207abcc92ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02171","BK1161","BK1574","BK1585","BK1587"],"gpt_icon":0},{"id":"2484062451","title":"科济药业-B(02171)授出266.7万份购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2484062451","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484062451?lang=zh_cn&edition=full","pubTime":"2024-11-18 20:51","pubTimestamp":1731934295,"startTime":"0","endTime":"0","summary":"科济药业-B(02171)公布，于2024年11月18日，公司根据首次公开发售后购...","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_20.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_20.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212523.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","02171","BK1161","BK1587","BK1585"],"gpt_icon":0},{"id":"2483813749","title":"科济药业-B(02171)下跌10.01%，报6.56元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483813749","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483813749?lang=zh_cn&edition=full","pubTime":"2024-11-14 13:08","pubTimestamp":1731560907,"startTime":"0","endTime":"0","summary":"11月14日，科济药业-B(02171)盘中下跌10.01%，截至13:08，报6.56元/股，成交7625.11万元。科济药业控股有限公司是一家专注于开发创新嵌合抗原受体T细胞（CAR-T）疗法，治疗实体瘤和血液恶性肿瘤的生物制药公司。其主要产品包括用于治疗复发/难治多发性骨髓瘤的自体BCMA CAR-T细胞产品泽沃基奥仑赛注射液，以及全球首个进入确证性临床试验的靶向Claudin18.2的自体CAR-T细胞候选产品，用于治疗胃癌、胰腺癌及其他实体瘤的舒瑞基奥仑赛注射液。截至2024年中报，科济药业-B营业总收入634.0万元、净利润-3.52亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/14130845281371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02171","BK1587","BK1574","BK1161","BK1585"],"gpt_icon":0},{"id":"2483988828","title":"科济药业-B盘中异动 股价大跌5.21%报6.910港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483988828","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483988828?lang=zh_cn&edition=full","pubTime":"2024-11-14 09:40","pubTimestamp":1731548428,"startTime":"0","endTime":"0","summary":"2024年11月14日早盘09时40分，科济药业-B股票出现异动，股价大幅下挫5.21%。截至发稿，该股报6.910港元/股，成交量112.1万股，换手率0.20%，振幅5.90%。资金方面，该股资金流入213.263万港元，流出446.371万港元。科济药业-B股票所在的生物技术行业中，整体跌幅为0.27%。其相关个股中，晶泰科技、迈博药业-B、宜明昂科-B涨幅较大，振幅较大的相关个股有晶泰科技、宜明昂科-B、科济药业-B，振幅分别为16.46%、5.79%、5.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114094028971a66da&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114094028971a66da&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","BK1161","BK1574","02171","BK1587"],"gpt_icon":0},{"id":"2483189290","title":"科济药业-B(02171)下跌5.21%，报7.83元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483189290","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483189290?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:08","pubTimestamp":1731463736,"startTime":"0","endTime":"0","summary":"11月13日，科济药业-B(02171)盘中下跌5.21%，截至10:08，报7.83元/股，成交2435.28万元。科济药业控股有限公司是一家专注于开发创新嵌合抗原受体T细胞（CAR-T）疗法，治疗实体瘤和血液恶性肿瘤的生物制药公司。其主要产品包括用于治疗复发/难治多发性骨髓瘤的自体BCMA CAR-T细胞产品泽沃基奥仑赛注射液，以及全球首个进入确证性临床试验的靶向Claudin18.2的自体CAR-T细胞候选产品，用于治疗胃癌、胰腺癌及其他实体瘤的舒瑞基奥仑赛注射液。截至2024年中报，科济药业-B营业总收入634.0万元、净利润-3.52亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13100845230977.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1587","BK1574","BK1585","BK1161","02171"],"gpt_icon":0},{"id":"2483101388","title":"科济药业-B盘中异动 早盘急速下跌5.33%报7.820港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483101388","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483101388?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:07","pubTimestamp":1731463626,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘10时07分，科济药业-B股票出现波动，股价大幅跳水5.33%。截至发稿，该股报7.820港元/股，成交量298.95万股，换手率0.52%，振幅5.45%。资金方面，该股资金流入727.947万港元，流出1322.31万港元。科济药业-B股票所在的生物技术行业中，整体跌幅为1.69%。其相关个股中，腾盛博药-B、贝康医疗-B、正大企业国际涨幅较大，振幅较大的相关个股有宜明昂科-B、乐普生物-B、来凯医药-B，振幅分别为19.44%、11.27%、9.70%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113100706971a62bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113100706971a62bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","BK1161","BK1574","02171","BK1587"],"gpt_icon":0},{"id":"2482722067","title":"科济药业-B11月12日获主力加仓454万元 环比增加45300.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482722067","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482722067?lang=zh_cn&edition=full","pubTime":"2024-11-12 16:15","pubTimestamp":1731399328,"startTime":"0","endTime":"0","summary":"11月12日, 科济药业-B股价跌2.36%，报收8.26元，成交金额1.62亿元，换手率3.43%，振幅10.40%，量比0.44。科济药业-B今日主力资金净流入454万元，上一交易日主力净流入1万元，今日环比增加45300.00%。该股近5个交易日上涨70.35%，主力资金累计净流入1526万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2178万元，其中净流入天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112161631abb9330b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112161631abb9330b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02171","BK1585","BK1161","BK1574","BK1587"],"gpt_icon":0},{"id":"2482797642","title":"科济药业-B盘中异动 早盘股价大跌5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482797642","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482797642?lang=zh_cn&edition=full","pubTime":"2024-11-12 09:44","pubTimestamp":1731375886,"startTime":"0","endTime":"0","summary":"2024年11月12日早盘09时44分，科济药业-B股票出现异动，股价快速下挫5.20%。截至发稿，该股报8.020港元/股，成交量414.8万股，换手率0.73%，振幅9.22%。科济药业-B股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，瑞科生物-B、乐普生物-B、方达控股涨幅较大，振幅较大的相关个股有绿竹生物-B、和誉-B、科济药业-B，振幅分别为18.42%、12.23%、9.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112094446abb79730&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112094446abb79730&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02171","BK1587","BK1574","BK1161","BK1585"],"gpt_icon":0},{"id":"2482244106","title":"科济药业-B(02171)上涨20.24%，报9.09元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482244106","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482244106?lang=zh_cn&edition=full","pubTime":"2024-11-11 11:23","pubTimestamp":1731295394,"startTime":"0","endTime":"0","summary":"11月11日，科济药业-B(02171)盘中上涨20.24%，截至11:23，报9.09元/股，成交2.17亿元。科济药业控股有限公司是一家专注于开发创新嵌合抗原受体T细胞（CAR-T）疗法，治疗实体瘤和血液恶性肿瘤的生物制药公司。其主要产品包括用于治疗复发/难治多发性骨髓瘤的自体BCMA CAR-T细胞产品泽沃基奥仑赛注射液，以及全球首个进入确证性临床试验的靶向Claudin18.2的自体CAR-T细胞候选产品，用于治疗胃癌、胰腺癌及其他实体瘤的舒瑞基奥仑赛注射液。截至2024年中报，科济药业-B营业总收入634.0万元、净利润-3.52亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/11112345135370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1585","BK1587","02171","BK1574","BK1161"],"gpt_icon":0},{"id":"2482451372","title":"东曜药业-B盘中异动 早盘股价大涨8.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482451372","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482451372?lang=zh_cn&edition=full","pubTime":"2024-11-11 10:18","pubTimestamp":1731291498,"startTime":"0","endTime":"0","summary":"2024年11月11日早盘10时18分，东曜药业-B股票出现异动，股价急速上涨8.28%。截至发稿，该股报1.830港元/股，成交量800股，换手率0.00%，振幅0.00%。东曜药业-B股票所在的生物技术行业中，整体跌幅为0.83%。东曜药业-B公司简介：东曜药业股份有限公司是一家临床阶段生物制药公司,主要从事开发及商业化肿瘤药物及疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111101818abb45d0a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111101818abb45d0a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1161","BK1585","02171","BK1574","01875"],"gpt_icon":0},{"id":"1148345557","title":"异动解读 | 科济药业CT0590通用型CAR-T疗法数据亮眼 股价大涨13.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148345557","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148345557?lang=zh_cn&edition=full","pubTime":"2024-11-11 10:01","pubTimestamp":1731290461,"startTime":"0","endTime":"0","summary":"科济药业-B今日盘中股价飙升13.1%,最高升至8.4港元,引发市场高度关注。此前科济药业宣布,其通用型CAR-T细胞疗法CT0590的数据将在美国血液学会年会上公布。据透露,CT0590研究的初步结果表明该通用型CAR-T细胞疗法的安全性可控,同时实现了深度和持久的临床缓解效果。业内分析指出,传统CAR-T疗法面临成本高昂、生产周期长等瓶颈,而通用型CAR-T有望极大提高该疗法的可及性,因此科济药业的CT0590如能持续显示令人信服的数据,未来市场前景广阔。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"gpt_icon":0},{"id":"2482124861","title":"港股异动 | 科济药业-B(02171)再涨超10% CT0590通用型CAR-T细胞疗法安全性可控 市场潜力巨大","url":"https://stock-news.laohu8.com/highlight/detail?id=2482124861","media":"智通财经","labels":["Product Release","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482124861?lang=zh_cn&edition=full","pubTime":"2024-11-11 09:53","pubTimestamp":1731290013,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B再涨超10%，截至发稿，涨9.92%，报8.3港元，成交额8296.87万港元。其中，CT0590研究初步结果表明，CT0590通用型CAR-T细胞疗法的安全性可控，同时实现了深度和持久的临床缓解。科济药业表示，与自体CAR-T相比，通用型CAR-T的成本将大大降低，且因其“货供应”的特点，患者等待时间缩短，将极大程度提高CAR-T的可及性，突破现有细胞治疗的行业瓶颈，具有巨大的市场潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1209042.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"Product Release,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1587","BK1161","BK4022","CAR","BK4230","BK1585","02171"],"gpt_icon":1},{"id":"2482457210","title":"科济药业-B盘中异动 大幅拉升5.03%报7.940港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2482457210","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482457210?lang=zh_cn&edition=full","pubTime":"2024-11-11 09:37","pubTimestamp":1731289045,"startTime":"0","endTime":"0","summary":"2024年11月11日早盘09时37分，科济药业-B股票出现异动，股价急速上涨5.03%。截至发稿，该股报7.940港元/股，成交量384.15万股，换手率0.67%，振幅8.07%。资金方面，该股资金流入1464.41万港元，流出789.889万港元。科济药业-B股票所在的生物技术行业中，整体跌幅为0.67%。其相关个股中，和誉-B、贝康医疗-B、康宁杰瑞制药-B涨幅较大，振幅较大的相关个股有和誉-B、科济药业-B、宜明昂科-B，振幅分别为9.76%、8.07%、6.98%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111109372598e41a25&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111109372598e41a25&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","BK1587","BK1574","BK1161","02171"],"gpt_icon":0},{"id":"2482243304","title":"南向资金11月8日净买入科济药业-B394.40万股 连续7日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2482243304","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482243304?lang=zh_cn&edition=full","pubTime":"2024-11-11 09:30","pubTimestamp":1731288616,"startTime":"0","endTime":"0","summary":"11月8日, 南向资金增持科济药业-B394.40万股，连续7日增持。截止当日收盘，港股通共持有科济药业-B14225.55万股，占流通股24.88%。科济药业-B近5个交易日上涨57.83%，港股通累计增持783.15万股；近20个交易日上涨59.16%，港股通累计增持1805.10万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111093233abb43d94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111093233abb43d94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","02171","BK1587","BK1585"],"gpt_icon":0},{"id":"1186652193","title":"异动解读 | 科济药业(02171)股价两日暴涨80% 免疫细胞疗法产品CT0590临床数据亮眼引发市场乐观情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1186652193","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186652193?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:57","pubTimestamp":1731056227,"startTime":"0","endTime":"0","summary":"科济药业在最近两个交易日内股价表现引发了市场的广泛关注,股价累计大涨超过80%。这一暴涨行情的主要推手是公司旗下新型免疫细胞疗法产品CT0590在最新临床试验中取得令人鼓舞的数据。同时,该疗法的整体安全性可控。作为一种针对多发性骨髓瘤等难治性血液肿瘤的新型疗法,CT0590如果顺利上市将为相关患者带来新的治疗选择。这为科济药业在免疫细胞疗法等创新药领域的长期发展奠定了雄厚基础,推升了市场对公司前景的信心。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"gpt_icon":0},{"id":"2481191641","title":"医药股早盘部分走高 科济药业-B涨超33%康宁杰瑞制药-B涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481191641","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481191641?lang=zh_cn&edition=full","pubTime":"2024-11-08 11:59","pubTimestamp":1731038378,"startTime":"0","endTime":"0","summary":"医药股早盘部分走高 ，科济药业-B（02171）上涨32.34%，报8.88港元；康宁杰瑞制药-B（09966）上涨8.01%，报4.18港元；云顶新耀-B（01952）上涨5.23%，报34.20港元；乐普生物-B（02157）上涨4.59%，报3.19港元；宜明昂科-B（01541）上涨3.28%，报7.54港元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-08/doc-incvinss3992567.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-08/doc-incvinss3992567.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1585","BK1161","BK1515","BK1574","02171","BK1587","09966","09939"],"gpt_icon":0},{"id":"2481416046","title":"港股异动 | 部分医药股走高 医保谈判支持创新药 机构指板块仍有进一步修复空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2481416046","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481416046?lang=zh_cn&edition=full","pubTime":"2024-11-08 10:48","pubTimestamp":1731034083,"startTime":"0","endTime":"0","summary":"消息面上，据国家医保局此前介绍，2024年国家医保药品目录调整现场谈判已顺利结束，“扩容”后的新版医保药品目录预计于11月底对外发布，2025年1月1日起正式实施。西南证券表示，创新药国谈和三季报落地。创新药国谈方向投资机会值得期待。交银国际表示，近期医药板块在大幅震荡后小幅回升，考虑到板块估值仍处于历史底部、叠加后续宏观利好政策出台+流动性改善，该行认为仍有进一步修复空间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208351.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","02171","01952","BK1583","BK1161","06978","02157","BK1585","159992","09966","BK1587","09939","BK1574"],"gpt_icon":0},{"id":"2481164550","title":"东曜药业-B盘中异动 早盘快速上涨7.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481164550","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481164550?lang=zh_cn&edition=full","pubTime":"2024-11-08 10:19","pubTimestamp":1731032352,"startTime":"0","endTime":"0","summary":"2024年11月08日早盘10时19分，东曜药业-B股票出现波动，股价大幅上涨7.65%。东曜药业-B股票所在的生物技术行业中，整体涨幅为0.76%。其相关个股中，科济药业-B、康宁杰瑞制药-B、帝王国际投资涨幅较大，振幅较大的相关个股有科济药业-B、康宁杰瑞制药-B、帝王国际投资，振幅分别为29.66%、19.64%、15.79%。东曜药业-B公司简介：东曜药业股份有限公司是一家临床阶段生物制药公司,主要从事开发及商业化肿瘤药物及疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110810191298e415b3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110810191298e415b3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02171","BK1587","BK1574","01875","BK1585","BK1161","09966"],"gpt_icon":0},{"id":"2481139162","title":"科济药业-B早盘涨逾22% 通用型CAR-T产品CT0590临床数据亮眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2481139162","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481139162?lang=zh_cn&edition=full","pubTime":"2024-11-08 09:50","pubTimestamp":1731030600,"startTime":"0","endTime":"0","summary":"　　科济药业-B早盘继续走高，该股昨日收涨逾41%，两个交易日累涨八成。截至发稿，股价上涨21.92%，现报8.18港元，成交额1.29亿港元。　　科济药业此前宣布其产品赛恺泽、CT071和CT0590的数据将在第66届美国血液学会年会上以壁报形式展示，会议将于12月7日至10日举行。科济药业靶向BCMA的通用型CAR-T产品CT0590的首个人体一期试验中，共入组5名受试者，中位随访时间16.6个月。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-08/doc-incvihkr2205219.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-08/doc-incvihkr2205219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1585","BK1574","02171","BK4230","BK4022","CAR","BK1587","BK1161"],"gpt_icon":0},{"id":"1156063492","title":"异动解读 | 科济药业(02171)股价两日大涨八成 通用型CAR-T产品CT0590临床数据亮眼引发市场乐观情绪","url":"https://stock-news.laohu8.com/highlight/detail?id=1156063492","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156063492?lang=zh_cn&edition=full","pubTime":"2024-11-08 09:43","pubTimestamp":1731030180,"startTime":"0","endTime":"0","summary":"港股科济药业在最近两个交易日内股价大涨超过80%,引发了市场的广泛关注。导致这一涨势的主要原因是其新型免疫细胞治疗产品CT0590在最新临床试验中取得了亮眼数据。这一初步数据引发了投资者的乐观预期。科济药业在免疫细胞疗法领域的产品管线进展顺利,被市场视为该公司长期增长潜力的一个重要支撑因素,从而推升了股价大涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":-0.2565},{"period":"1month","weight":0.5686},{"period":"3month","weight":0.6338},{"period":"6month","weight":-0.0218},{"period":"1year","weight":-0.4521},{"period":"ytd","weight":-0.0323}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"科济药业控股有限公司是一家主要从事创新嵌合抗原受体（CAR）T 细胞疗法发现、开发及销售业务的中国投资控股公司。该公司的疗法用于治疗血液恶性肿瘤和实体瘤。该公司已开发升级版靶向B细胞成熟抗原（BCMA）的CAR-T产品CT053。CT053为其的唯一核心候选产品。该公司在中国和美国开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.177045},{"month":2,"riseRate":0.666667,"avgChangeRate":0.218959},{"month":3,"riseRate":0,"avgChangeRate":-0.160429},{"month":4,"riseRate":0,"avgChangeRate":-0.124967},{"month":5,"riseRate":0.666667,"avgChangeRate":0.010432},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.000476},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003478},{"month":8,"riseRate":0.5,"avgChangeRate":0.066002},{"month":9,"riseRate":0.5,"avgChangeRate":0.083194},{"month":10,"riseRate":0.75,"avgChangeRate":0.067361},{"month":11,"riseRate":0.5,"avgChangeRate":0.032292},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.177104}],"exchange":"SEHK","name":"科济药业-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科济药业-B,02171,科济药业-B股票,科济药业-B股票老虎,科济药业-B股票老虎国际,科济药业-B行情,科济药业-B股票行情,科济药业-B股价,科济药业-B股市,科济药业-B股票价格,科济药业-B股票交易,科济药业-B股票购买,科济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}